AG˹ٷ

STOCK TITAN

[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Barclays Bank PLC is issuing $452,000 of unsecured, unsubordinated Buffered Supertrack SM Notes linked to the price return of the Russell 2000 Index (RTY). The notes are part of the bank’s Global Medium-Term Notes, Series A and will be offered in $1,000 denominations on 30 Jun 2025, maturing 30 Dec 2027.

  • Payout profile � If the index is flat or up at maturity, investors receive principal plus 2× upside, capped at a 31.35 % maximum return ($1,313.50 per $1,000 note).
  • Downside buffer � First 10 % decline is fully protected. Below the 90 % Buffer Value (1,922.57), losses are linear: every additional 1 % drop erodes 1 % of principal, up to a 90 % loss.
  • Key parameters: Initial Value 2,136.185; Upside Leverage 2.0; Buffer 10 %; CUSIP 06746BX71; Estimated value on pricing date $965.70 (�3.4 % below issue price).
  • Costs & liquidity: 2.75 % selling commission; no exchange listing; Barclays Capital intends, but is not obliged, to make a secondary market.
  • Credit & regulatory risk: Payments depend on Barclays� creditworthiness and are subject to the U.K. Bail-in Power, meaning principal could be written down or converted to equity during resolution.
  • Tax & withholding: Issuer views the notes as prepaid forward contracts; U.S. tax treatment uncertain; Section 871(m) not expected to apply (delta � 1).

The structure targets investors who can forgo coupons, accept a capped return, and tolerate meaningful equity and issuer risk in exchange for a modest downside buffer and enhanced—though limited—upside participation.

Barclays Bank PLC emette 452.000 $ di Buffered Supertrack SM Notes non garantite e non subordinate, collegate al rendimento del prezzo dell'indice Russell 2000 (RTY). Le note fanno parte della Serie A dei Global Medium-Term Notes della banca e saranno offerte in tagli da 1.000 $ il 30 giugno 2025, con scadenza il 30 dicembre 2027.

  • Profilo di rendimento � Se l'indice è stabile o in crescita alla scadenza, gli investitori ricevono il capitale più un guadagno doppio rispetto alla crescita, con un rendimento massimo del 31,35% (1.313,50 $ per ogni nota da 1.000 $).
  • Protezione dal ribasso � Il primo 10% di calo è completamente protetto. Sotto il valore di buffer del 90% (1.922,57), le perdite sono lineari: ogni ulteriore calo dell'1% riduce l'1% del capitale, fino a una perdita massima del 90%.
  • Parametri chiave: Valore iniziale 2.136,185; Leva sul rialzo 2,0; Buffer 10%; CUSIP 06746BX71; Valore stimato alla data di prezzo 965,70 $ (circa 3,4% sotto il prezzo di emissione).
  • Costi e liquidità: Commissione di vendita 2,75%; nessuna quotazione in borsa; Barclays Capital intende, ma non è obbligata, a creare un mercato secondario.
  • Rischio di credito e regolamentare: I pagamenti dipendono dalla solvibilità di Barclays e sono soggetti al potere di bail-in del Regno Unito, il che significa che il capitale potrebbe essere ridotto o convertito in azioni durante la risoluzione.
  • Fiscalità e ritenute: L'emittente considera le note come contratti forward prepagati; trattamento fiscale USA incerto; la Sezione 871(m) probabilmente non si applica (delta � 1).

La struttura è rivolta a investitori disposti a rinunciare a cedole, accettare un rendimento massimo e tollerare rischi significativi legati all'equity e all'emittente, in cambio di una protezione modesta dal ribasso e di una partecipazione aumentata, seppur limitata, al rialzo.

Barclays Bank PLC está emitiendo 452.000 $ en Buffered Supertrack SM Notes no garantizadas y no subordinadas, vinculadas al rendimiento del precio del índice Russell 2000 (RTY). Las notas forman parte de la Serie A de los Global Medium-Term Notes del banco y se ofrecerán en denominaciones de 1.000 $ el 30 de junio de 2025, con vencimiento el 30 de diciembre de 2027.

  • Perfil de pago � Si el índice está estable o sube al vencimiento, los inversores reciben el principal más el doble de la subida, con un rendimiento máximo del 31,35% (1.313,50 $ por cada nota de 1.000 $).
  • Protección a la baja � La primera caída del 10% está totalmente protegida. Por debajo del valor de buffer del 90% (1.922,57), las pérdidas son lineales: cada caída adicional del 1% reduce el 1% del principal, hasta una pérdida máxima del 90%.
  • Parámetros clave: Valor inicial 2.136,185; Apalancamiento al alza 2,0; Buffer 10%; CUSIP 06746BX71; Valor estimado en la fecha de precio 965,70 $ (aproximadamente 3,4% por debajo del precio de emisión).
  • Costos y liquidez: Comisión de venta 2,75%; sin cotización en bolsa; Barclays Capital tiene la intención, pero no está obligado, a crear un mercado secundario.
  • Riesgo crediticio y regulatorio: Los pagos dependen de la solvencia de Barclays y están sujetos al poder de rescate (bail-in) del Reino Unido, lo que significa que el principal podría reducirse o convertirse en acciones durante la resolución.
  • Fiscalidad y retenciones: El emisor considera las notas como contratos forward prepagados; tratamiento fiscal en EE.UU. incierto; no se espera que se aplique la Sección 871(m) (delta � 1).

La estructura está dirigida a inversores que pueden renunciar a cupones, aceptar un rendimiento máximo y tolerar riesgos significativos de acciones y del emisor a cambio de una protección modesta a la baja y una participación mejorada, aunque limitada, al alza.

Barclays Bank PLC� Russell 2000 지�(RTY)� 가� 수익률에 연동� 452,000달러 규모� 무담�, 비후순위 Buffered Supertrack SM Notes� 발행합니�. � 노트들은 은행의 글로벌 중기채권 시리� A� 속하�, 2025� 6� 30일에 1,000달러 단위� 제공되어 2027� 12� 30일에 만기됩니�.

  • 지� 프로� � 만기 � 지수가 변� 없거� 상승하면 투자자는 원금� 2배의 상승 수익� 받으�, 최대 수익� 31.35% (1,000달러� 1,313.50달러)� 상한� 설정됩니�.
  • 하락 방어 � 최초 10% 하락은 전액 보호됩니�. 90% 버퍼 �(1,922.57) 이하에서� 손실� 선형적으� 발생하며, 추가 1% 하락 � 원금� 1%가 감소� 최대 90% 손실까지 가능합니다.
  • 주요 파라미터: 초기 � 2,136.185; 상승 레버리지 2.0; 버퍼 10%; CUSIP 06746BX71; 가� 책정� 추정 가� 965.70달러 (발행가 대� � 3.4% 낮음).
  • 비용 � 유동�: 판매 수수� 2.75%; 거래� 상장 없음; Barclays Capital은 2� 시장 조성� 의도하나 의무� 없습니다.
  • 신용 � 규제 위험: 지급은 Barclays� 신용도에 따라 달라지�, 영국� 베일� 권한 대상이므� 원금� 감액되거� 주식으로 전환� � 있습니다.
  • 세금 � 원천징수: 발행자는 � 노트� 선불 선도 계약으로 간주하며, 미국 세금 처리 불확�; 섹션 871(m)은 적용되지 않을 것으� 예상(delta � 1).

� 구조� 쿠폰 지급을 포기� � 있고, 최대 수익� 수용하며, 상당� 주식 � 발행� 위험� 감내� � 있는 투자자를 대상으� 하며, 이에 대� 보상으로 적당� 하락 방어와 제한적이지� 향상� 상승 참여 기회� 제공합니�.

Barclays Bank PLC émet 452 000 $ de Buffered Supertrack SM Notes non garanties et non subordonnées, liées au rendement en prix de l'indice Russell 2000 (RTY). Ces notes font partie de la série A des Global Medium-Term Notes de la banque et seront proposées en coupures de 1 000 $ le 30 juin 2025, avec une échéance au 30 décembre 2027.

  • Profil de remboursement � Si l'indice est stable ou en hausse à l'échéance, les investisseurs reçoivent le capital plus deux fois la hausse, plafonné à un rendement maximal de 31,35 % (1 313,50 $ par note de 1 000 $).
  • Protection à la baisse � La première baisse de 10 % est entièrement protégée. En dessous de la valeur tampon de 90 % (1 922,57), les pertes sont linéaires : chaque baisse supplémentaire de 1 % réduit le capital de 1 %, jusqu'à une perte maximale de 90 %.
  • Paramètres clés : Valeur initiale 2 136,185 ; effet de levier à la hausse 2,0 ; tampon 10 % ; CUSIP 06746BX71 ; valeur estimée à la date de tarification 965,70 $ (environ 3,4 % en dessous du prix d'émission).
  • Coûts et liquidité : commission de vente de 2,75 % ; pas de cotation en bourse ; Barclays Capital a l'intention, mais n'est pas obligé, de créer un marché secondaire.
  • Risques de crédit et réglementaires : les paiements dépendent de la solvabilité de Barclays et sont soumis au pouvoir de bail-in du Royaume-Uni, ce qui signifie que le capital pourrait être réduit ou converti en actions lors d'une résolution.
  • Fiscalité et retenues : l'émetteur considère les notes comme des contrats à terme prépayés ; traitement fiscal américain incertain ; la section 871(m) ne devrait pas s'appliquer (delta � 1).

Cette structure cible les investisseurs capables de renoncer aux coupons, d'accepter un rendement plafonné et de tolérer des risques importants liés aux actions et à l'émetteur, en échange d'une protection modérée à la baisse et d'une participation accrue, bien que limitée, à la hausse.

Barclays Bank PLC gibt unbesicherte, nicht nachrangige Buffered Supertrack SM Notes im Wert von 452.000 $ aus, die an die Kursentwicklung des Russell 2000 Index (RTY) gekoppelt sind. Die Notes sind Teil der Global Medium-Term Notes, Serie A, der Bank und werden am 30. Juni 2025 in Stückelungen von 1.000 $ angeboten, mit Fälligkeit am 30. Dezember 2027.

  • Auszahlungsprofil � Liegt der Index bei Fälligkeit stabil oder im Plus, erhalten Anleger den Nennwert plus das 2-fache des Anstiegs, begrenzt auf eine maximale Rendite von 31,35 % (1.313,50 $ pro 1.000 $ Note).
  • Abwärts-Puffer � Der erste 10%-Rückgang ist vollständig geschützt. Unterhalb des 90%-Buffer-Werts (1.922,57) sind Verluste linear: Jeder weitere 1%-Rückgang mindert den Nennwert um 1 %, bis zu einem maximalen Verlust von 90 %.
  • Wichtige Parameter: Anfangswert 2.136,185; Upside-Leverage 2,0; Puffer 10 %; CUSIP 06746BX71; Geschätzter Wert am Pricing-Tag 965,70 $ (ca. 3,4 % unter dem Ausgabepreis).
  • Kosten & Liquidität: 2,75 % Verkaufsprovision; keine Börsennotierung; Barclays Capital beabsichtigt, aber ist nicht verpflichtet, einen Sekundärmarkt zu schaffen.
  • Kredit- & regulatorisches Risiko: Zahlungen hängen von der Bonität von Barclays ab und unterliegen der britischen Bail-in-Regelung, was bedeutet, dass der Nennwert während einer Abwicklung reduziert oder in Eigenkapital umgewandelt werden kann.
  • Steuer & Quellensteuer: Der Emittent betrachtet die Notes als vorausbezahlte Terminkontrakte; US-Steuerbehandlung ungewiss; Abschnitt 871(m) wird voraussichtlich nicht angewandt (Delta � 1).

Die Struktur richtet sich an Anleger, die auf Kupons verzichten können, eine begrenzte Rendite akzeptieren und bedeutende Aktien- und Emittentenrisiken tolerieren, im Austausch für einen moderaten Abwärtspuffer und eine verbesserte, wenn auch begrenzte, Aufwärtsbeteiligung.

Positive
  • 10 % downside buffer absorbs moderate equity declines before principal is at risk.
  • 2× upside participation up to a 31.35 % cap enables enhanced returns versus direct RTY exposure within a defined range.
  • Short 2.5-year tenor reduces duration exposure relative to longer-dated structured notes.
Negative
  • Maximum return is capped at 31.35 %, limiting gains if the Russell 2000 rallies strongly.
  • Up to 90 % principal loss once the index falls more than 10 %, exposing investors to significant downside.
  • Estimated value ($965.70) is materially below issue price, indicating ~3.4 % embedded costs at launch.
  • Issuer credit and U.K. bail-in risk mean repayment depends on Barclays� solvency and regulatory actions.
  • No exchange listing and small deal size could result in poor secondary-market liquidity.

Insights

TL;DR � Leverage to 31 % upside with 10 % buffer, but high issuer and liquidity risk makes outcome highly path-dependent.

The notes offer a clear risk-reward trade-off: double the small-cap upside until 15.675 % index appreciation, after which returns are capped. The 10 % buffer is typical for two-to-three-year retail structures and will only absorb mild equity drawdowns; beyond that, losses accelerate 1-for-1. Investors effectively exchange dividend rights and uncapped growth for leveraged but limited participation plus serious tail risk. Pricing is expensive: the bank’s own model value ($965.70) sits 34.3 points below issue price, largely covering the 2.75 % commission, hedging costs and issuer margin. Credit exposure to Barclays and potential bail-in further differentiate this from traditional debt.

Because secondary liquidity is dealer-driven, exit pricing will incorporate both bid/ask spreads and issuer credit spreads, typically leaving early sellers at a material discount. The small $452k deal size suggests limited aftermarket depth. Overall, the note may suit fee-based accounts seeking defined-outcome exposure to U.S. small caps over 30 months, provided they are comfortable with credit, liquidity, and buffer limitations.

TL;DR � Niche, short-dated defined-outcome note best viewed as tactical satellite, not core holding.

Strategically, the instrument behaves like a short-put/long-call spread on the Russell 2000 layered over a Barclays credit note. At issuance, the embedded option premium (difference between $1,000 price and $965.70 model value) approximates 3.5 %, implying investors overpay relative to delta-hedged replication. The 31.35 % cap translates to an annualized 11.8 % max yield—attractive if the investor’s bullish view materializes inside two years, but structurally inferior to simply holding RTY ETF beyond the cap. In stressed equity markets, the 90 % potential loss combined with Barclays� bail-in risk could materially impair portfolios. Thus, allocation should be limited and paired with diversified credit exposure.

Barclays Bank PLC emette 452.000 $ di Buffered Supertrack SM Notes non garantite e non subordinate, collegate al rendimento del prezzo dell'indice Russell 2000 (RTY). Le note fanno parte della Serie A dei Global Medium-Term Notes della banca e saranno offerte in tagli da 1.000 $ il 30 giugno 2025, con scadenza il 30 dicembre 2027.

  • Profilo di rendimento � Se l'indice è stabile o in crescita alla scadenza, gli investitori ricevono il capitale più un guadagno doppio rispetto alla crescita, con un rendimento massimo del 31,35% (1.313,50 $ per ogni nota da 1.000 $).
  • Protezione dal ribasso � Il primo 10% di calo è completamente protetto. Sotto il valore di buffer del 90% (1.922,57), le perdite sono lineari: ogni ulteriore calo dell'1% riduce l'1% del capitale, fino a una perdita massima del 90%.
  • Parametri chiave: Valore iniziale 2.136,185; Leva sul rialzo 2,0; Buffer 10%; CUSIP 06746BX71; Valore stimato alla data di prezzo 965,70 $ (circa 3,4% sotto il prezzo di emissione).
  • Costi e liquidità: Commissione di vendita 2,75%; nessuna quotazione in borsa; Barclays Capital intende, ma non è obbligata, a creare un mercato secondario.
  • Rischio di credito e regolamentare: I pagamenti dipendono dalla solvibilità di Barclays e sono soggetti al potere di bail-in del Regno Unito, il che significa che il capitale potrebbe essere ridotto o convertito in azioni durante la risoluzione.
  • Fiscalità e ritenute: L'emittente considera le note come contratti forward prepagati; trattamento fiscale USA incerto; la Sezione 871(m) probabilmente non si applica (delta � 1).

La struttura è rivolta a investitori disposti a rinunciare a cedole, accettare un rendimento massimo e tollerare rischi significativi legati all'equity e all'emittente, in cambio di una protezione modesta dal ribasso e di una partecipazione aumentata, seppur limitata, al rialzo.

Barclays Bank PLC está emitiendo 452.000 $ en Buffered Supertrack SM Notes no garantizadas y no subordinadas, vinculadas al rendimiento del precio del índice Russell 2000 (RTY). Las notas forman parte de la Serie A de los Global Medium-Term Notes del banco y se ofrecerán en denominaciones de 1.000 $ el 30 de junio de 2025, con vencimiento el 30 de diciembre de 2027.

  • Perfil de pago � Si el índice está estable o sube al vencimiento, los inversores reciben el principal más el doble de la subida, con un rendimiento máximo del 31,35% (1.313,50 $ por cada nota de 1.000 $).
  • Protección a la baja � La primera caída del 10% está totalmente protegida. Por debajo del valor de buffer del 90% (1.922,57), las pérdidas son lineales: cada caída adicional del 1% reduce el 1% del principal, hasta una pérdida máxima del 90%.
  • Parámetros clave: Valor inicial 2.136,185; Apalancamiento al alza 2,0; Buffer 10%; CUSIP 06746BX71; Valor estimado en la fecha de precio 965,70 $ (aproximadamente 3,4% por debajo del precio de emisión).
  • Costos y liquidez: Comisión de venta 2,75%; sin cotización en bolsa; Barclays Capital tiene la intención, pero no está obligado, a crear un mercado secundario.
  • Riesgo crediticio y regulatorio: Los pagos dependen de la solvencia de Barclays y están sujetos al poder de rescate (bail-in) del Reino Unido, lo que significa que el principal podría reducirse o convertirse en acciones durante la resolución.
  • Fiscalidad y retenciones: El emisor considera las notas como contratos forward prepagados; tratamiento fiscal en EE.UU. incierto; no se espera que se aplique la Sección 871(m) (delta � 1).

La estructura está dirigida a inversores que pueden renunciar a cupones, aceptar un rendimiento máximo y tolerar riesgos significativos de acciones y del emisor a cambio de una protección modesta a la baja y una participación mejorada, aunque limitada, al alza.

Barclays Bank PLC� Russell 2000 지�(RTY)� 가� 수익률에 연동� 452,000달러 규모� 무담�, 비후순위 Buffered Supertrack SM Notes� 발행합니�. � 노트들은 은행의 글로벌 중기채권 시리� A� 속하�, 2025� 6� 30일에 1,000달러 단위� 제공되어 2027� 12� 30일에 만기됩니�.

  • 지� 프로� � 만기 � 지수가 변� 없거� 상승하면 투자자는 원금� 2배의 상승 수익� 받으�, 최대 수익� 31.35% (1,000달러� 1,313.50달러)� 상한� 설정됩니�.
  • 하락 방어 � 최초 10% 하락은 전액 보호됩니�. 90% 버퍼 �(1,922.57) 이하에서� 손실� 선형적으� 발생하며, 추가 1% 하락 � 원금� 1%가 감소� 최대 90% 손실까지 가능합니다.
  • 주요 파라미터: 초기 � 2,136.185; 상승 레버리지 2.0; 버퍼 10%; CUSIP 06746BX71; 가� 책정� 추정 가� 965.70달러 (발행가 대� � 3.4% 낮음).
  • 비용 � 유동�: 판매 수수� 2.75%; 거래� 상장 없음; Barclays Capital은 2� 시장 조성� 의도하나 의무� 없습니다.
  • 신용 � 규제 위험: 지급은 Barclays� 신용도에 따라 달라지�, 영국� 베일� 권한 대상이므� 원금� 감액되거� 주식으로 전환� � 있습니다.
  • 세금 � 원천징수: 발행자는 � 노트� 선불 선도 계약으로 간주하며, 미국 세금 처리 불확�; 섹션 871(m)은 적용되지 않을 것으� 예상(delta � 1).

� 구조� 쿠폰 지급을 포기� � 있고, 최대 수익� 수용하며, 상당� 주식 � 발행� 위험� 감내� � 있는 투자자를 대상으� 하며, 이에 대� 보상으로 적당� 하락 방어와 제한적이지� 향상� 상승 참여 기회� 제공합니�.

Barclays Bank PLC émet 452 000 $ de Buffered Supertrack SM Notes non garanties et non subordonnées, liées au rendement en prix de l'indice Russell 2000 (RTY). Ces notes font partie de la série A des Global Medium-Term Notes de la banque et seront proposées en coupures de 1 000 $ le 30 juin 2025, avec une échéance au 30 décembre 2027.

  • Profil de remboursement � Si l'indice est stable ou en hausse à l'échéance, les investisseurs reçoivent le capital plus deux fois la hausse, plafonné à un rendement maximal de 31,35 % (1 313,50 $ par note de 1 000 $).
  • Protection à la baisse � La première baisse de 10 % est entièrement protégée. En dessous de la valeur tampon de 90 % (1 922,57), les pertes sont linéaires : chaque baisse supplémentaire de 1 % réduit le capital de 1 %, jusqu'à une perte maximale de 90 %.
  • Paramètres clés : Valeur initiale 2 136,185 ; effet de levier à la hausse 2,0 ; tampon 10 % ; CUSIP 06746BX71 ; valeur estimée à la date de tarification 965,70 $ (environ 3,4 % en dessous du prix d'émission).
  • Coûts et liquidité : commission de vente de 2,75 % ; pas de cotation en bourse ; Barclays Capital a l'intention, mais n'est pas obligé, de créer un marché secondaire.
  • Risques de crédit et réglementaires : les paiements dépendent de la solvabilité de Barclays et sont soumis au pouvoir de bail-in du Royaume-Uni, ce qui signifie que le capital pourrait être réduit ou converti en actions lors d'une résolution.
  • Fiscalité et retenues : l'émetteur considère les notes comme des contrats à terme prépayés ; traitement fiscal américain incertain ; la section 871(m) ne devrait pas s'appliquer (delta � 1).

Cette structure cible les investisseurs capables de renoncer aux coupons, d'accepter un rendement plafonné et de tolérer des risques importants liés aux actions et à l'émetteur, en échange d'une protection modérée à la baisse et d'une participation accrue, bien que limitée, à la hausse.

Barclays Bank PLC gibt unbesicherte, nicht nachrangige Buffered Supertrack SM Notes im Wert von 452.000 $ aus, die an die Kursentwicklung des Russell 2000 Index (RTY) gekoppelt sind. Die Notes sind Teil der Global Medium-Term Notes, Serie A, der Bank und werden am 30. Juni 2025 in Stückelungen von 1.000 $ angeboten, mit Fälligkeit am 30. Dezember 2027.

  • Auszahlungsprofil � Liegt der Index bei Fälligkeit stabil oder im Plus, erhalten Anleger den Nennwert plus das 2-fache des Anstiegs, begrenzt auf eine maximale Rendite von 31,35 % (1.313,50 $ pro 1.000 $ Note).
  • Abwärts-Puffer � Der erste 10%-Rückgang ist vollständig geschützt. Unterhalb des 90%-Buffer-Werts (1.922,57) sind Verluste linear: Jeder weitere 1%-Rückgang mindert den Nennwert um 1 %, bis zu einem maximalen Verlust von 90 %.
  • Wichtige Parameter: Anfangswert 2.136,185; Upside-Leverage 2,0; Puffer 10 %; CUSIP 06746BX71; Geschätzter Wert am Pricing-Tag 965,70 $ (ca. 3,4 % unter dem Ausgabepreis).
  • Kosten & Liquidität: 2,75 % Verkaufsprovision; keine Börsennotierung; Barclays Capital beabsichtigt, aber ist nicht verpflichtet, einen Sekundärmarkt zu schaffen.
  • Kredit- & regulatorisches Risiko: Zahlungen hängen von der Bonität von Barclays ab und unterliegen der britischen Bail-in-Regelung, was bedeutet, dass der Nennwert während einer Abwicklung reduziert oder in Eigenkapital umgewandelt werden kann.
  • Steuer & Quellensteuer: Der Emittent betrachtet die Notes als vorausbezahlte Terminkontrakte; US-Steuerbehandlung ungewiss; Abschnitt 871(m) wird voraussichtlich nicht angewandt (Delta � 1).

Die Struktur richtet sich an Anleger, die auf Kupons verzichten können, eine begrenzte Rendite akzeptieren und bedeutende Aktien- und Emittentenrisiken tolerieren, im Austausch für einen moderaten Abwärtspuffer und eine verbesserte, wenn auch begrenzte, Aufwärtsbeteiligung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dorton Katina

(Last) (First) (Middle)
C/O FULCRUM THERAPEUTICS, INC.
26 LANDSDOWNE STREET

(Street)
CAMBRIDGE MA 02139

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $7.38 06/26/2025 A 36,000 (1) 06/25/2035 Common Stock 36,000 $0.00 36,000 D
Explanation of Responses:
1. This option was granted on June 26, 2025 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
/s/ Greg Tourangeau, as attorney-in-fact for Katina Dorton 06/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What is the upside cap for Barclays VXZ Buffered Supertrack Notes?

The notes cap total return at 31.35 %, delivering a maximum payment of $1,313.50 per $1,000 note.

How much protection does the 10 % buffer provide on the Russell 2000 Index?

If the index ends within 10 % below its initial level, investors receive full principal; below that, losses are 1-for-1.

What are the key dates for these 424B2 notes?

Initial Valuation 25 Jun 2025; Issue 30 Jun 2025; Final Valuation 27 Dec 2027; Maturity 30 Dec 2027.

How do selling commissions impact investor proceeds?

Barclays Capital earns a 2.75 % commission, contributing to the gap between the $1,000 price and $965.70 estimated value.

Are the notes listed or easily tradable before maturity?

No. The notes will not be listed; any secondary trading depends solely on dealer willingness, with potentially wide spreads.

How does the U.K. Bail-in Power affect investors?

Regulators can write down or convert the notes if Barclays is in resolution, which could wipe out principal irrespective of index performance.
Fulcrum Therapeutics

NASDAQ:FULC

FULC Rankings

FULC Latest News

FULC Latest SEC Filings

FULC Stock Data

373.54M
52.99M
1.87%
97.18%
9.11%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE